1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Zur Rose Group AG
  6. Summary
    ROSE   CH0042615283

ZUR ROSE GROUP AG

(ROSE)
  Report
Delayed Swiss Exchange  -  11:31 2022-08-09 am EDT
59.85 CHF   -13.88%
01:30aZUR ROSE GROUP : Barclays is Neutral
MD
08/03ZUR ROSE GROUP : UBS maintains a Sell rating
MD
07/19ZUR ROSE GROUP : Barclays remains its Buy rating
MD
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
08/03/2022 08/04/2022 08/05/2022 08/08/2022 08/09/2022 Date
72.4(c) 72.6(c) 67.7(c) 69.5(c) 59.85 Last
144 889 99 076 114 401 66 578 303 583 Volume
-1.76% +0.28% -6.75% +2.66% -13.88% Change
More quotes
Estimated financial data (e)
Sales 2022 1 743 M 1 829 M 1 829 M
Net income 2022 -169 M -177 M -177 M
Net Debt 2022 445 M 467 M 467 M
P/E ratio 2022 -4,34x
Yield 2022 -
Sales 2023 2 235 M 2 344 M 2 344 M
Net income 2023 -126 M -132 M -132 M
Net Debt 2023 563 M 590 M 590 M
P/E ratio 2023 -5,89x
Yield 2023 -
Capitalization 724 M 759 M 759 M
EV / Sales 2022 0,67x
EV / Sales 2023 0,58x
Nbr of Employees 2 131
Free-Float 85,3%
More Financials
Company
Zur Rose Group AG is a Switzerland-based company engaged in the drug distribution sector. The Company focuses on the wholesale trade of medicines, as well as operation of a mail-order pharmacy. The Company's activities are divided into two business segments: Zur Rose and DocMorris. The Zur Rose division includes wholesale business and provides drugs to medical doctors, health insurance companies, hospitals and... 
Sector
Drug Retailers
Calendar
08/18 | 01:00amEarnings Release
More about the company
Ratings of Zur Rose Group AG
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about ZUR ROSE GROUP AG
01:30aZUR ROSE GROUP : Barclays is Neutral
MD
08/03ZUR ROSE GROUP : UBS maintains a Sell rating
MD
07/19ZUR ROSE GROUP : Barclays remains its Buy rating
MD
07/18ZUR ROSE GROUP : Credit Suisse reiterates its Sell rating
MD
07/12Deutsche Bank Lowers Price Target on Zur Rose Group, Downgrades Recommendation to Hold ..
MT
07/12ZUR ROSE GROUP : Deutsche Bank is now Neutral
MD
06/30ZUR ROSE GROUP : Barclays gives a Buy rating
MD
06/22ZUR ROSE : Tobias Leipold, CEO and Co-Founder, leaves eHealth-Tec GmbH
PU
06/22ZUR ROSE GROUP : Credit Suisse reaffirms its Sell rating
MD
06/17ZUR ROSE : Tobias Leipold, CEO and Co-Founder, leaves eHealth-Tec GmbH
PU
06/08ZUR ROSE GROUP : Gets a Sell rating from UBS
MD
06/07ZUR ROSE GROUP : Barclays keeps its Buy rating
MD
06/07Aevis Victoria Buys Stake In Swiss Digital Health Platform Well
MT
06/06ZUR ROSE GROUP : Deutsche Bank reaffirms its Buy rating
MD
06/01ZUR ROSE GROUP : Jefferies maintains a Buy rating
MD
More news
News in other languages on ZUR ROSE GROUP AG
11:39aAktien Schweiz mit Abgaben - Warten auf US-Verbraucherpreise
08:43aAKTIEN FRANKFURT : Verluste - Nervosität vor den US-Inflationsdaten wächst
06:04aAKTIEN EUROPA : EuroStoxx leicht im Minus - Zurückhaltung vor Inflationsdaten
05:31aBOURSE ZURICH : le doute s'installe en attendant l'inflation US
05:31aAKTIEN SCHWEIZ : Schwächere Kurse - Zurückhaltung vor US-Inflationsdaten
More news
Analyst Recommendations on ZUR ROSE GROUP AG
More recommendations
Chart ZUR ROSE GROUP AG
Duration : Period :
Zur Rose Group AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ZUR ROSE GROUP AG
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Last Close Price 69,50 CHF
Average target price 142,45 CHF
Spread / Average Target 105%
EPS Revisions
Managers and Directors
Walter Hess Chief Executive Officer
Marcel Ziwica Chief Financial Officer
Walter Oberhänsli Chairman
Madhu Nutakki Chief Technology Officer
Bernd Michael Gschaider Chief Operating Officer
Sector and Competitors